Efficacy of alogliptin in preventing non-alcoholic fatty liver disease progression in patients with type 2 diabetes
Tsuyoshi Mashitani(Nara Medical University), Hitoshi Yoshiji(Nara Medical University), Hiroto Moriyasu(Nara City Hospital), Masami Matsumoto(Nara City Hospital), Hiromasa Ohira(Fukushima Medical University), Tadashi Namisaki(Nara Medical University), Tatsuichi An(Berurando General Hospital), Atsuko Kogure, Hitoshi Ishii(Nara Medical University), Akira Mitoro(Nara Medical University), Kazuhiro Noguchi(Japanese Red Cross Society, Japan), Ryuichi Noguchi(Nara Medical University), SIGEYUKI AIZAWA(National Archives and Records Administration), Hiroshi Morita(Shinshu University), Shinya Sato(Kyushu University), Yasushi Okura(Nara Medical University), Eiryo Kikuchi(National Archives and Records Administration), Toshiya Nakatani(Kindai University), Masatoshi Ishikawa(Yao Tokushukai General Hospital), Yoshinobu Matsumura(Yao Tokushukai General Hospital), Yasunori Tokuoka(Nara City Hospital)
Cited by 43
Related Papers
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
Genome-wide Association Study Identifies TNFSF15 and POU2AF1 as Susceptibility Loci for Primary Biliary Cirrhosis in the Japanese Population
|The American Journal of Human Genetics|2012|272
A nationwide survey on non-B, non-C hepatocellular carcinoma in Japan: 2011–2015 update
|Journal of Gastroenterology|2018|242
Evidence‐based clinical practice guidelines for liver cirrhosis 2020
|Hepatology Research|2021|202
Gut Dysbiosis Associated With Hepatitis C Virus Infection
|Clinical Infectious Diseases|2018|187